The USA-based company's lead candidate, CAP-1002, is an 'off-the-shelf' cardiac cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy (DMD).

In October 2017, Capricor reported results from its Phase I/II HOPE clinical trial of CAP-1002 showing that teens and young men in the advanced stages of DMD experienced meaningful improvements in cardiac and upper limb function after a single dose the drug. These results sent the company's share price soaring by more than 21%.